Dr. Guo-Liang Yu is the global CEO of Apollomics Inc. (Formerly CBT Pharmaceuticals), an innovative therapeutics company devoted to curingcancer by combining immunology and other caner fighting methods. Before Apollomics Inc., Dr. Yu was the Executive Chairman of Crown Biosicence Inc., a publically-listed personalized oncology platform company with ~600 employees globally. Crown Bioscience was acquired by JSR for $400 million in May of 2018. He co-founded Epitomics Inc., an antibody biotechnology company, and served as Chairman and  
CEO for 10 years prior to its acquisition by Abcam for $170 million. He was also a venture partner at OrbiMed Venture LLC.  
Dr. Yu’s success is driven by his scientific curiosity and passion for translating scientific discovery to real products. After graduating from Fudan University in Shanghai, China, he came to the United States in 1984 to pursue advanced studies. He obtained his Ph.D. from UC Berkeley, where he and Dr. Greider discovered telomerase and its mechanism in Dr. Blackburn’s lab. Drs. Blackburn and Greider received Nobel Prize in 2009 for their discovery. Dr. Yu later joined Dr. Frederick Ausubel’s lab at Harvard University to pursue the question of how plants defend themselves against pathogens without an immune system, and identified the plant disease resistance gene. In 1993, when genomics was still in its infancy, Dr. Yu joined Human Genome Sciences Inc. as one of the first few senior scientists, identifying human gene targets for drug discovery. Among several important drug targets he studied was BLys, the first successfully genomic target for the development of a lupus antibody drug Benlysta, which was approved by FDA in 2010.  

In 1998, Dr. Yu was attracted to identifying plant genes with economic value in agriculture and in bio-energy. He was Senior Vice President of R&D at Mendel Biotechnology Inc. where his team analyzed the function of a complete set of plant transcription factors, and ultimately identified several valuable traits such as enhanced crop yield, disease resistance, and drought tolerance. Dr. Yu has co-authored 43 peer-reviewed scientific articles that have been referenced by the scientific community over 6000 times. He is a co-inventor of more than 400 patents.  

Dr. Yu is the founding president of the Chinese Biopharmaceutical Association (CBA) and serves on the boards of several professionalorganizations in the United States and China, including BayHelix, Chinese-American Bio/Pharmaceutical Society (CABS), National Foundation of Cancer Research, Ray Wu Memorial Foundation, and University of Pacific. Dr. Yu is generous in coaching young entrepreneurs, and he has co-founded a dozen startup companies in biotech and the healthcare sector, including Immune-Onc Therapeutics, Inc.in Palo Alto. 

Throughout her long career in science, Dr. Blackburn has been a leader in the area of telomere and telomerase research, having discovered the molecular nature of telomeres – the ends of eukaryotic chromosomes that serve as protective caps essential for preserving the genetic information – and co-discovered the ribonucleoprotein enzyme, telomerase. She is also known for her championing of diversity and inclusion in the sciences. Currently, Dr. Blackburn and her UCSF research team continue their work with various cells (including human cells), with the goal of understanding telomerase and telomere biology. She and her research team also collaborate in a wide range of investigations of the roles of telomere biology in human health and diseases, through clinical and other human studies. 

Born in Australia, Dr. Blackburn earned her B.Sc. and M.Sc. degrees from the University of Melbourne, and her Ph.D. from the University of Cambridge in England. She was a postdoctoral fellow in the Molecular and Cellular Biology Department at Yale University. Professor Blackburn has won many prestigious awards throughout her career including Nobel Prize in Physiology or Medicine, the Albert Lasker Medical Research Award for Basic Medical Research, and in 2007 was named one of TIME Magazine’s 100 Most Influential People. 

Throughout her long career in science, Dr. Blackburn has been a leader in the area of telomere and telomerase research, having discovered the molecular nature of telomeres – the ends of eukaryotic chromosomes that serve as protective caps essential for preserving the genetic information – and co-discovered the ribonucleoprotein enzyme, telomerase. She is also known for her championing of diversity and inclusion in the sciences. Currently, Dr. Blackburn and her UCSF research team continue their work with various cells (including human cells), with the goal of understanding telomerase and telomere biology. She and her research team also collaborate in a wide range of investigations of the roles of telomere biology in human health and diseases, through clinical and other human studies.
Born in Australia, Dr. Blackburn earned her B.Sc. and M.Sc. degrees from the University of Melbourne, and her Ph.D. from the University of Cambridge in England. She was a postdoctoral fellow in the Molecular and Cellular Biology Department at Yale University. Professor Blackburn has won many prestigious awards throughout her career including Nobel Prize in Physiology or Medicine, the Albert Lasker Medical Research Award for Basic Medical Research, and in 2007 was named one of TIME Magazine’s 100 Most Influential People.

Dr. Baoqun Fan is a well-recognized leader in economic and industrial policy, enterprise development policy, and enterprise innovation.  He is the Assistant Dean of the National School of Development at Peking University, where he also serves as the Sinar Mas Chair Researcher. Previously, Dr. Fan was a policy researcher at the Development Research Center of the State Council, and has also held a Visiting Professorship at Stanford University.  
Dr. Fan has published numerous academic papers and reports on economic policy, and has received prestigious awards recognizing his contribution to the scientific and technological progress of Zhejiang Province. Dr. Fan received his Ph.D. in Management from Zhejiang University in 1999. 

• Ph.D. from Zhejiang University of Management, 1999 
• Engaged in operation and management at ZTE corporation, 1999-2003 
• Policy researcher at Development Research Center of the State Council, 2003-2016 
• Visiting Professor of Stanford University, 2004 and 2010 
• Research fellow of Development Research Center of the State Council 
• Assistant Dean of National School of Development at Peking University, Since 2016 
• Sinar Mas Chair Researcher at Peking University 

Mr. Ruilin Song is the Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Expert of the Talent Pool for State Affairs of Chinese People's Political Consultative Conference (CPPCC), and Expert for State Affairs of Central Committee of Chinese Peasants and Workers Democratic Party. He holds an LLB from the China University of Political Science and Law, EMBA from China Europe International Business School, and a Doctorate of Social and Administrative Pharmacy from China Pharmaceutical University, and is a Visiting Scholar of the University of Sydney. Mr. Song has served for many years in the Legislative Affairs Office at State Council of China, engaging in health and drug policy, legal studies, and legislation in the pharmaceutical and healthcare industry. He has made great contributions towards the reform of drug review and approval system, the medical insurance reimbursement system, and policies for pharmaceutical innovation in China.   

Currently, Mr. Song also holds several prominent leadership positions, such as Executive Deputy Director of the Research Center of National Drug Policy & Ecosystem of China Pharmaceutical University, Guest Research Professor of Shanghai Jiao Tong University, Biotech Advisory Panel Member of the Stock Exchange of Hong Kong Limited, the Vice President of China Alliance for Rare Disease (CARD), Director of Chinese Pharmaceutical Association (CPA), Director of Chinese Pharmacists Association and Director of Bethune Charitable Foundation. 

Dr. Ramesh Kolluru serves as the Associate Provost and Vice President for Research, Innovation and Economic Development at the University of Louisiana at Lafayette. He is a nationally recognized leader in the areas of science and technology, translational and public-impact research, economic and workforce development, as well as innovation and entrepreneurship. He is a tenured Professor in the School of Computing and Informatics, with expertise in computing, health innovation, homeland security and emergency management, public-private partnerships, data science and big data, among others. In his role as Vice President for Research, Dr. Kolluru establishes strategic vision for the University of Louisiana in expanding its regional, national, and global impact through research, innovation, and economic development.
In recognition of his expertise as a leader in health innovation, Dr. Kolluru was appointed into the role of Chief Innovation Officer for the US Department of Health and Human Services in Washington, D.C, during 2019 and 2020. He worked on expanding the role of data science, AI, and innovation in the delivery of health and human services to all Americans by HHS. Dr. Kolluru has also been appointed by FEMA Administrator to the FEMA National Advisory Council where he chairs the FEMA Vision 2045 Committee.
Born and raised in India, Dr. Kolluru has lived in Lafayette for over 25 years. Recipient of the Governor’s Technology Leader of the Year award in 2008, he is prouder of the title “Honorary Cajun” bestowed on him by Lafayette Parish-President Mayor Joey Durel. His proudest titles, however, are husband, dad, speech-coach, friend, dish-washer, and chauffeur!

Dalun Gao, graduated from the History Department of Northwest University. Previously worked in Sichuan University, Sichuan Provincial Museum (acting curator), Sichuan Provincial Bureau of Cultural Relics (Deputy Director), Sichuan Provincial Institute of Cultural Relics and Archaeology (Dean 2002-2018). He served as the executive director of the Chinese Archaeological Society, the vice president of the Chinese Qin and Han History Research Association, and the president of the Sichuan Folklore Society. 
Mr. Gao Dalun served as the leader of the expert supervision team for the third Sichuan Provincial Cultural Relics Census (2007-2012), the planning and construction expert team of the Sichuan Earthquake Relics Museum and the Sichuan Provincial Seismic Cultural Relics Collection Expert Team (2008-2012). Won the special allowance of the State Council (2007), won the Sichuan Provincial Party Committee and Provincial Government's First Outstanding Talent Award (2016), and the Ministry of Culture Advanced Individual (2012). 
The main research direction is archeology and museology. He has published more than 10 professional works, and published more than 100 research papers and translations. Since entering the new century, it has actively explored and expanded new areas of archaeological research, advocated and actively practiced the protection, planning and utilization of archaeological cultural heritage led by archaeologists, and has dozens of various case works. 

Dr. Ruyi He is the Chief Medical Officer of RemeGen CO., Ltd. and Chief Scientist of SDIC Fund Management CO., LTD and former Chief Scientist at the Center for Drug Evaluation at the National Medical Products Administration (NMPA). Dr. He joined NMPA in July 2016, after having worked at the US Food and Drug Administration (FDA) for more than 17 years. Dr. He was the first overseas expert hired by NMPA as the Chief Scientist.  He participated in and organized many recent Chinese FDA reforms on the drug evaluation system including numerous technique guidances for drug evaluation and approval in China.   

Dr. He joined the US Center for Drug Evaluation and Research (CDER) at the US FDA in 1999 as a Medical Officer in the Division of Gastrointestinal and Coagulation Drug Products. He became a Medical Team Leader in 2003 and later served as the Acting Deputy Director for years. He chaired several working groups that were tasked with drafting and finalizing guidelines for industry, and was also involved in FDA guidance development in multiple therapeutic areas. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, DC. and received his clinical and research training at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) in Bethesda, Maryland. Dr. He is a licensed, board-certified physician in Internal Medicine in the USA. 

Dr. Senping Cheng, who has over 10 years’ entrepreneurial experience in China and the United States, founded Triastek in 2015 and served as the CEO of the company. 

As the only pharmaceutical company specializing in 3D printing of drug products in China, Triastek invented a revolutionary pharmaceutical 3D printing technology, known as Melt Extrusion Deposition (MED®), and has established a comprehensive 3D printing pharmaceutical technology platform for dosage form design, product development, and intelligent manufacturing. The company has filed 124 international patent applications in the related field with 32 patents granted. Using MED® 3D printing technology, Triastek has developed 505(b)(2) product portfolio in-house to meet specific clinical needs and improve the outcomes of drug therapy. Triastek’s Investigational New Drug (IND) application for its first 3D printed drug product – T19, indicated for the treatment of rheumatoid arthritis (RA), has been approved by the United States Food and Drug Administration (FDA) in January, 2021. 

Prior to Triastek, Dr. Cheng founded two companies, one in San Francisco in 2010 and the other in Nanjing in 2014.   

Dr. Cheng obtained her Bachelor degree in Clinical Medicine from Nanjing Medical University, and Ph.D. degree in Toxicology from the University of Kentucky.  She holds 15 patents with 83 patent applications pending and has published more than 20 research articles, and is also an Adjunct Professor of Pharmaceutics in Thomas J. Long School of Pharmacy and Health Sciences at the University of the Pacific. 

Dr. Dong Shen is the founder and president of RNAimmune. Previously, Dr. Shen served as a director of oncology at Janssen Pharmaceutical, a company of Johnson and Johnson. Dr. Shen graduated with PhD degree from Johns Hopkins University School of Medicine and MD degree from Shanghai Jiao Tong University School of Medicine. Dr. Shen led TCGA breast cancer, lung cancer, ovary cancer and AML projects. All his manuscripts been published at top peer reviewed journals, such as New England Journal of medicine, Nature, Science, Cell, JAMA, Nature genetics, etc. The total number of his citations is over 18,681. In 2018, Dr. Dong Shen was elected as the President of Chinese Biopharmaceutical association (CBA) and the Chair of CBA board of directors with over 8,000 registered members. 

Sophie Sun is the Senior Vice President of Corporate Development, in charge of strategy, business development and commercialization for the Company.  Ms. Sun joins Apollomics from Merck KGaA, where she was most recently Vice President & Managing Director, Innovation Hubs China.  In this role, Ms. Sun oversaw Merck KGaA’s development partnerships in China for China and global markets.  She was with Merck KGaA for twelve years holding multiple roles of increasing responsibility in both strategic markets of China and US, as well as global organizations, such as Commercial Director of Global Oncology Franchise for oncology new product planning and launch.  During her tenure with Merck KGaA, Sophie participated in 9 new product launches in China, US locally or for global markets.  
Prior to Merck KGaA, Ms. Sun spent over eight years at marketing agencies Interpublic Group (IPG) and WPP, where she worked for many Fortune 500 companies covering a wide range of industries. Ms. Sun received a master’s degree from Renmin University of China, and a Master of Business Administration from MIT Sloan School of Management. Sophie translated and published two books in psychology management area and is an active speaker and advocate on female leadership, innovation and entrepreneurship. Sophie is a member of the BayHelix Group and served as a board member for MIT Alumni Club of Shanghai. She is also Forbes China 2021 Chinese Women in Tech, and 2020 Outstanding Innovators of Science and Technology selected by Economic Observer. 

Jay Lin is the Senior Director External Innovation of Discovery, Product Development & Supply (DPDS) at Johnson & Johnson Innovation, Asia Pacific. In this role, he has overall strategic and operational responsibility for the scouting and evaluation of external opportunities for DPDS in Asia Pacific across all biologic and synthetic drug modalities. As a bench scientist in his early career where he focused on research and development (R&D), Jay worked for three companies before joining JNJ and quickly progressed into leading search and evaluation in business development where he travelled the world to look for the best and latest innovation. Fast forward to today, Jay sees great potential in Asia’s fast-growing biotech innovation ecosystem and is actively seeking revolutionary life science innovation in the region. Jay acquired his Ph.D. in Microbiology/Immunology and Biomedical Engineering from the University of Texas at Austin and Bachelor degree from Zhejiang University 

Jian Ma, Ph.D., is co-founder and CEO of XtalPi, overseeing business operations as well as research and product development. Prior to founding XtalPi in 2014, Dr. Ma served as a postdoctoral associate at the Massachusetts Institute of Technology, and was visiting scholar at RIKEN in Japan and The Chinese University of Hong Kong, during which time he completed extensive research on quantum information, quantum computing, and numerical simulation. Dr. Ma has published over twenty peer-reviewed articles on top scholarly publications, including Physics Reports, Physical Reiview and Journal of Chemical Physics.

Dr. Ma earned his doctorate and B.S. in Physics at Zhejiang University.

Ray Yang is a Partner at Marathon Venture Partners (MVP), a China-based early to growth stage fund focusing on digital healthcare transformation.  

Prior to MVP, Mr. Yang was a Managing Director at Northern Light Venture Capital, where he led the firm’s investments both in Healthcare and technology. He started his venture capital career with Orchid Asia Group Management in 2004, where he helped establish the firm’s China operations and served as an Investment Director. Mr. Yang’s notable investments include Thundersoft (300469), Burning Rock Biotech (BNR)，BGI (300676), AnnoroadGenomics, AnchorDX, iRay Technology (688301); Datsing Bio-techscience, Golden Leaf MedTec, Micropoint Bioscience (835054), InCarey Medical, Shukun Technology; Meditrust Medical; Vedeng Medical; MYZH; Soonsolid; Nanos Medical; WeMed Medical, Yunnan Newcare, Nurse-Link, Credible (CRD) and etc.. 

Prior to his venture capital career, Mr. Yang has spent ten years in various Chinese government and multinational corporations. He worked at the China’s Ministry of Commerce and as a Vice Commercial Consul for the Chinese Consulate General in Houston, Texas. He also worked as a Commodities Trader for Louis Dreyfus Corporation. Mr. Yang is a member of Bayhelix, he was the Co-Chair of China Healthcare Investment 50 Forum (H50). Mr. Yang holds a bachelor’s degree in Economics from Shanghai Institute of Foreign Trade and an M.B.A from Harvard Business School. 

James Chou is the Managing Director and CEO of Microsoft for Startups North Asia, Chair of Technology and Innovation Committee of American Chamber of Commerce Shanghai. At Microsoft, he leads the effort to scale-up some of the best and most innovative startups in China, Japan and Korea by providing them unprecedented access to top Microsoft customers and venture capitalists.   The total valuation of Microsoft for Startups portfolio in China has exceeded $30 Billion. He is a frequent speaker on corporate open innovation and China startups, also an advisor to several VC funds, an advisory board member to several leading Fortune 500 companies’ corporate accelerators in China. He has over 20 years experiences in TMT space in China and Silicon Valley, US. Before Microsoft, he was a serial entrepreneur and served senior management positions at UTStarcom, Hewlett Packard and NEC. 

 

Dasheng Cai is a tenor, music educator and professor living in Europe. Lifelong singer of the Gothenburg Opera House, the Swedish National Theater, and the Norwegian National Opera. 

In 1988, he went to Sweden at his own expense to participate in the international opera master class competition, won the Swedish National Supreme Art Fund Award and studied in Sweden. In the past two decades in Europe, he has performed in more than 20 countries including the United Kingdom, France, Italy, Germany, Belgium, Czech Republic, Denmark, Hungary, the United States, Austria, etc. It is the opera with the most Chinese singers on the international stage. He is regarded as one of the most influential Chinese singers in the world by the Ministry of Culture. 

Participated in the performances of CCTV Spring Festival, National Day, New Year's Day and Mid-Autumn Festival. Served as a judge for the three major events of China Golden Bell Award, CCTV Young Singer Competition and Ministry of Culture Young Singer Competition. 

Since 2012, Cai Dasheng initiated and founded "Sing for You" one hundred charity concerts. In 2019, Cai Dasheng was invited three times to lead outstanding Chinese young singers to perform in Europe.

Dr. Hang Lu has served as a director of Development Service, CDMO at Emergent BioSolutions, a NYSE-listed public global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations. Dr. Lu has extensive working experience in biologics development as well as CDMO service after working at Emergent BioSolutions and Merck Co. for more than twenty years. Dr. Lu was responsible for set-up the immunotoxicology lab at MRL and GxP lab at Emergent. He contributed to the development of several traditional and new generation vaccines and biologics from the discovery, preclinical and CMC development, technical transfer in the stages of R&D, phase 1 or phase 3 or post approval submissions leading to regulatory approvals in USA.  

Dr. Lu obtained his medical degree from Zhejiang University. He completed post-doctoral research training at the University of British Columbia with a sponsorship from the Canadian Institutes of Health Research.  

Dr. Lu is the current President of the Chinese Biopharmaceutical Association (CBA). 

Dr. Patrick Y. Lu, Ph.D., founder, Chairman of Board, President and CEO, has over 28 years of biopharma research and development experience in China and the U.S. After 7 years working at Novartis gene therapy division, Dr. Lu co-founded Intradigm Corp. in 2001 in the U.S., serving as its executive vice president and leading the company's siRNA therapeutic research and development until early 2007. After leaving Intradigm, Patrick founded Sirnaomics, Inc. in the spring of 2007 and then established Sirnaomics Suzhou (2008) and Sirnaomics Guangzhou (2012). Dr. Lu has led team building up a robust technology platform and a enriched siRNA therapeutic product pipeline, and raised more than US$270 million investment. Dr. Lu has authored over 55 scientific publications, is an inventor on 53 patents and has been recognized with multiple awards and grants in China and the U.S. for his innovative research and entrepreneurship. 

Dajun Yang, Ph.D., is the Co-Founder, Chairman of the Board, and Chief Executive Officer of Ascentage Pharma. Dr. Yang has dedicated his career to the research on apoptosis and innovative drug R&D for nearly 30 years. In 2009, he co-founded Ascentage Pharma and made major breakthroughs in the research of development of precision drugs targeting apoptosis and autophagy dual-channel regulation. Ascentage Pharma is the only company in the world that researches and develops innovative drugs targeting all of these pathways. Ascentage Pharma currently has eight potential “First-in-class” or “Best-in-class” innovative drug candidates in Phase I/II clinical developments in China, the United States, Australia and Europe. Dr. Yang has undertaken nearly ten National Science and Technology Major Projects such as the National High-tech R&D Program (the “863 Program”) and the Major Innovative Drug Developments program. The team led by Dr. Yang has won multiple awards such as the Major Innovation Team of Suzhou and Jiangsu, the First Jiangsu Innovation Competition Team Award, and the R&D Achievement of the Year 2017 from the BayHelix Group. Dr. Yang is the recipient of the 2018 “Dushu Lake Prize” for the Most Influential Leader in Drug R&D， an award widely recognized in the field drug R&D. Dr. Yang was the president of Chinese Biopharmaceutical Association-USA from 2005 to 2006 and has concurrently served as professor and Ph.D. supervisor at Sun Yat-sen University Cancer Center, director of the Drug R&D Specialty Committee of China Pharmaceutical Innovation and Research Development Association, and part-time researcher in Pharmaceutical Innovations at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. 

Dr. Shou Bai CHAO, became executive director on June 22, 2018 and Chief Operating Officer （COO）on May 1, 2018. He is deputy general manager of our company and is primarily responsible for the management of daily operations and strategy development. In addition, Dr. Chao also oversees production management and quality control. With nearly 33 years' experience in the biotechnology industry, he formerly served as Vice President and Senior Vice President at AstraZeneca plc from January 2008 to April 2018. Prior to joining AstraZeneca in 2008, Dr. Chao also had worked for Wyeth, Genentech and Sanofi-Pasteur from 1993-2007 with increased responsibilities. Dr. Chao was president and the Board Director at the Chinese Biopharmaceutical Association  

Dr. Yuling Li is the co-founder and CEO of Innoforce Pharmaceuticals, a pharmaceutical development company established in 2018 at Hangzhou, China with the focus of building enabling capabilities for innovative drug development including monoclonal antibody, plasmid DNA/nucleic acid, viral vector and cell therapy products.  She was the Sr. Vice President of Process Development and Manufacturing of Apollomics (Foster City, CA and Hangzhou), the R&D Fellow/Director in BioPharmaceutical Development at MedImmune/AstraZeneca (Gaithersburg, MD), the Senior Director in BioPharmaceutical Development at Human Genome Sciences Inc. (now part of GSK, Rockville, MD) and an Associate Scientist at Hoffmann-La Roche Inc. in Nutley, New Jersey.  In the past 30 years, Dr. Li led CMC activities for 4 BLA/MAA submissions and 3 approved products (Belimumab, Raxibacumab and Brodalumab) and contributed to 30+ biopharmaceuticals through various clinical stages of CMC development.   
During the course of her career, Dr. Li published 40+ peer-reviewed articles and book chapters and is the inventor for five issued patents.   In 2014, Dr. Li received the Rising Star Award from the Healthcare Businesswomen Association. Dr. Li served as the President (2007-2008), Board of Directors, member of the Advisory Board for the Chinese Biopharmaceutical Association-USA (CBA, www.CBA-USA.org), a non-profit professional organization. Dr. Li also co-founded the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (ALL-CABPA) in 2008.  She is a BayHelix member. 

Dr. Zhang was the Head of Clinical Development and the Head of Safety Assessment at Sigma-Tau Research Inc. – a leading Italian Pharmaceutical Company. Prior to that, he was the vice president at the Quintiles Transnational Corp., the world largest clinical CRO, and Chairman of Quintiles Medical Development (Shanghai) Company Ltd.  

Yifan Zhai, M.D., Ph.D., is Chief Medical Officer of Ascentage Pharma, CEO at Guangzhou Healthquest Pharma. She has worked in new drug development for nearly 30 years in NCI/NIH, GSK, Bayer, Exelixis and others, including small molecules, antibody and vaccine based therapeutics. Under the leadership of Dr. Zhai, Ascentage Pharma has built a pipeline of eight clinical drug candidates, the company is conducting nearly 50 clinical trials in the US, Australia, Europe, and China, she is responsible for NDA submission of Olverembatinib in 2020 in China. Dr. Zhai has exceptional expertise and experience in pathology, pharmacology, toxicology and clinical research. She is one of the inventors and manufacturers of the world's first tumor vaccines, Ad2MART1 and Ad2GP100, and jointly developed Sorafenib (NEXAVAR®) as the patent co-inventors while working at Bayer. 

Dr. Zhai more than 50 publications and have more than 80 patent applications. She was selected as the Leading Talent of Guangzhou Science and Technology Innovation in 2012, the Leading Talent of Guangdong Science and Technology Innovation Team in 2013, and she named in “2020 Women in Tech” by Forbes China. Dr. Zhai was also the 12th President (2009-2010) of Chinese Biopharmaceutical Association, USA (CBA). 

Ziping Wei, PhD, is the co-founder, chairman and Chief Executive Officer of Bliss Biopharmaceutical (Hangzhou) Co., Ltd., focusing on the development and commercialization of innovative biological drugs. She has more than 20 years of experience in CMC development of innovative biologics in multinational biopharmaceutical companies in the US, and has valuable experience in promoting several biopharmaceuticals from lead candidates to approved new drugs for the market. She served at Novavax, AstraZeneca/MedImmune, Bristol-Myers Squibb, and Johnson & Johnson in the United States. She led teams to be involved in the CMC development of more than forty innovative biological drugs, including therapeutic monoclonal antibodies, bispecific antibodies, recombinant proteins, ADCs, fusion proteins, immunotoxins, and recombinant proteins/viral vaccines, of which nine products have been approved for market. She also participated in the USP expert panel for the drafting of Monoclonal Antibody General Chapter. She has co-authored over 30 journal publications, patents, book chapters, and more than 80 scientific abstracts and presentations in the international conferences.  
Dr. Wei received her Ph.D. in Chemistry at Rutgers, the State University of New Jersey, and B.S. in Chemistry at the University of Science and Technology of China. She is a former president (2014-2015) and a member of Board of Director of Chinese Biopharmaceutical Association-USA (CBA). 

Dr. Chen is one of the world leading scientists with more than 20 years of experiences in developing innovative gene medicine and molecular vaccine. Dr. Chen joined Genvec, a pioneer biotech company, as a scientist in 1996, worked as a leader in malaria vaccine research and development supported by funding from MVI and NIH SBIR. Dr. Chen is an expert in adenoviral vector design and construction with success in generating adenoviral vectors for delivery of multiple antigens.  Dr. Chen made an outstanding endeavor for a successful high throughput antigen discovery project and established a streamlined approach for identification of highly protective antigens for new vaccine, obtained patent for newly discovered malaria antigens. Dr. Chen has published more than 20 peer reviewed papers.

Dr. Chen is the founder and CEO/CSO of Jiaxing Anyu Biotechnology Co. since 2014, focused on new molecular vaccine development for infectious diseases. Dr. Chen has led his group and successfully built a macromolecular gene expression vector platform with intellectual property rights. Obtained cell line for packaging high-capacity macromolecular live vector vaccines; Established a unique production process for genetic vaccines, and Dr.Chen is advancing new genetic medicine and molecular vaccines to medical clinical applications.

Dr. Chen earned BA degree from Yu Zhou University at Chongqing in 1983, completed Master degree in the Institute of Developmental biology in Chinese Academy of Sciences in 1986, received Ph.D in molecular genetics from the University of Utah in 1995. 

Dr. Chen is the board director, and life-time member of CBA, he was the eighteenth president of CBA (2013-2014).

• M.S. from Shanghai Institute of Plant Physiology, Chinese Academy of Sciences; Ph.D. from University of Maryland, USA 
• Postdoctoral research in anti-tumor angiogenesis at Georgetown University Lombardi Cancer Center and in tumor immunotherapy at DR. Steven Rosenberg’s Laboratory in NCI, USA 
• With 18 years of experience in process development, project management and GMP facilities in Baxter, GenVec, AnGes and other biopharmaceutical companies 
• Engaged in multiple outsourced CMOs, CRO CMCs and clinical trial management, as well as business negotiations for project cooperation and transfer 
• Cofounded Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focusing on the 2nd generation cancer immunotherapeutic antibody drugs 

Chief Executive Officer, Nuance Biotech Co. Ltd., Vice President, Shanghai Society of Biotechnology, Vice President, Biotechnique Association of Jiangsu; Chairman, Committee of Interferon and Other Cytokines, Executive Director, Chinese Society of Microbiology; Chairman, Committee of Medicine and Pharmceuticals; Received many honors and awards, such as The National Science Fund for Distinguished Young Scholars , Award for national outstanding returned scholars, Second Prize of National Science and Technology Progress Award, Outstanding Achievement Award for Chinese Biopharmaceutical Association, USA, Privileged expert of China Department of State, Visiting Professor of Shanghai Jiao Tong University，Second Military Medical University and Nanjing Medical University.  
Dr. Jian Ni obtained Ph.D. from University of Cambridge, has published more than 121 scientific papers in top scientific journals (IF >600), Inventor of 283 issued US patents, 4 FDA approved antibody drugs and 10 antibody drugs in clinical trials were based on these inventions. First identified or published or patented several B7 superfamily members, such as B7-H1（PD-L1）、B7-H2（ICOSL）、B7-H3 and B7-H4， TNF ligands and receptor superfamily members, such as Blys/BAFF (THANK )、DR3（TNFR25）、 DR4、DR5、DR6、GITR（AITR， TNFR18）、GITRL、TR2/HVEM、LIGHT、TR6/DcR3、TL1A/VEGI、TR8/RANK、TNFRSF19、RELT、TR1（DcR3）、DcR1and DcR2， Siglecs family： Siglec 5， 7， 8， 9， 10， 11，and Galectin family： Galectin 9，10， 11， 12.  4-1BB and MyD88 are used in CAR-T.  A few apoptosis related genes discovered by Dr. Ni and his collaborators were reviewed by Science Journal as top ten breakthroughs of the year 1996. 

Dr. Chuanhua Julia Xing is the founder for Shihua Medical in Suzhou, China and XPrecision LLC in Maryland, the inventor for AI technology for cancer diagnosis and treatment, and a renowned AI expert. AI driven system medicine approach integrates more cancer signals for an earlier and more accurate detection and diagnosis, the optimal treatment strategies for maximizing the lifetime or even the cure for the cancer, and the discovery of the multi-gene targets for new drug development etc. Shihua has top tier expertise and experience in AI, medicine, and business, and has won multiple prestigious awards. Partnering with representative companies in US and China, Shihua is dedicated to leading AI technologies and products for resolving cancer and human complex diseases. 

Dr. Xing is 2019-2020 president for Chinese Biopharmaceutical Association – USA. She gained her Ph.D. from North Carolina State University and her postdoc from Duke University. She worked as an assistant professor at Boston University, a visiting professor at Sun Yat-sen University, a Principal Statistician at AstraZeneca MEDI and a Sr. Statistician Advisor for Dynport Vaccine Company. She has published near 30 papers with most as the lead author at the first tier/high impact journals. She is also a frequent interviewee and keynote speaker for representative meetings in US and China and has played the leadership roles in representative organizations, meetings, and journals. She has won multiple science and leadership awards including IFAH 2021 the Top 100 Healthcare Visionaries Award. 

Dr. Weili Hong is one of China’s leaders in the private equity and venture capital industry. He has served in prominent leadership roles such as CEO of CMC Holding Group, Managing Partner at Gopher Asset Management, and Manager at Zhongchuang Investment. Under his leadership, Gopher Asset Management’s team invested in over 100 PE/VC funds, becoming China’s foremost Fund of Funds. Dr. Hong is currently Visiting Professor of the School of Economics and Fanhai International School of Finance at Fudan University. He is also an investment partner at several first-tier funds, and chairs the board of several listed companies.  
After graduating from the Fudan University Department of Economics in 1992, Dr. Hong joined the newly founded Shanghai Stock Exchange, becoming a first-generation member of the regulatory authority. Later in the 1990s, he became one of China’s youngest senior executives in the brokerage field. 
Dr. Hong is also an experienced outdoor traveler and nature expert. He co-founded YeTravel.com, and has led hundreds of expeditions in over 70 countries, including dozens of trips in Tibet, and 7 journeys to the North and South Poles. 

Ning Li is currently the Chief Executive Officer at Shanghai Junshi Biosciences. Before he joined Junshi Biosciences, Dr. Li had been appointed as Vice President and Head of Region Asia and China Regulatory Affairs and Medical Policy in Sanofi. He has extensive experience and expertise in clinical research and medical product evaluation.  
Dr. Li worked at US Food and Drug Administration previously as a regulatory reviewer and held various positions from Oncology drug team reviewer, senior reviewer/expert reviewer, senior GCP medical reviewer to team leader, branch chief with increasing responsibilities. Dr. Li was a member of multiple technical committees and the lead or medical reviewer for dozens of new drug applications (NDA) and over 200 investigational new drug applications (IND). Prior to his US FDA career, Dr. Li served on the faculty of Internal Medicine Department at University of Iowa and Shanghai Medical University (Fudan University).  
Dr. Li obtained his medical degree from Shanghai Medical University (Fudan University) and a doctorate degree from University of Iowa. He has published more than 30 scientific papers in the area of clinical trial methodology.  
He is a member of Cooperative Drug Development Grants Review Committee, NIMH, NIH and Special Emphasis Panel NIDR, NIH, an adjunct faculty member at Johns Hopkins University and Peking University, a researcher at Yihong Business School of Shenyang Pharmaceutical University, and an academic advisor at the Pharmaceutical Economics Institute of Sun Yat-sen University. Dr. Li participated in the formulation of multiple FDA/NMPA clinical research technical guidelines. He has served as a member of the Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Committee since 2020. 

 

Ben Zhao is founder and CEO of The WhiteOak Group Inc. (TWG). Prior to TWG, Dr. Zhao is a CMC reviewer and GMP inspector specialized in complex drugs at the US FDA. In 2014, he founded TWG devoted to developing high-quality liposomal drugs with rational design. Previously, Dr. Zhao was a group leader in developing small interfering RNA (siRNA) at Abbott Laboratories. In China, he developed the first generic liposomal doxorubicin (Libaoduo®) in 2008. Dr. Zhao is an inventor of 12 patents and has published over twenty peer reviewed articles. He also serves as an Advisory Board member for the NSF Nanotechnology center. Dr. Zhao was trained as a medical doctor at Norman Bethune University of Medical Sciences and received a Ph.D. degree from the Ohio State University. 

Dr. Gang Chen currently is CSO in R&G PharmaStudies. Before joining R&G, Dr. Chen was Head of Quantitative Sciences, J&J China R&D from 2013 to 2016 and functional head of statistics for oncology drug development from 2003 to 2013 in J&J US. Prior to J&J, Dr. Chen had been working with US FDA as Team Leader for statistical review group in Oncology Drug Review Division from 1998 to 2003 and as a senior statistical reviewer from 1996 to 1998.  
Has been working in clinical research and drug development area across regulatory and industry and accumulated extensive experiences in drug development from both industry and regulatory perspectives. Contributed significantly in many statistical regulatory policy researches areas including, MRCT / bridging, non-inferiority, adaptive design，enrichment design and other research areas and published many important scientific research papers.  

Dr. Cao had over 20 years’ experience across academia， pharmaceutical industry and regulatory agency (US-FDA) in translational science, regulatory affairs and clinical development. Dr. Cao received his Ph.D. degree in Pharmaceutics from the Ohio State University and had been working with global pharmaceutical companies， Boehringer Ingelheim and Abbott Lab/Abbvie for ten years as global development Lead on multiple projects. In 2013, Dr. Cao joined FDA as the senior clinical pharmacologist in the Oncology Center of Excellence (OCE) for the submission of oncology and hematology products, and clinical pharmacology scientific team lead for the oncology biosimilar drug submissions. During his tenure in FDA, Dr. Cao had been the primary/secondary reviewer for clinical pharmacology for over 500 IND phase 1-phase 3 clinical trial protocols and lead for the approval for other over 10 NME NDA/BLA applications, including the OPDIVO ((nivolumab) 2014) approval in 1st indication of melanoma in US.   

Currently, I serve as the vice president in charge of project management and regulatory affairs for Beijing Chineo Medical, leading the company's pipeline advancement, quality system setup, non-clinical and clinical research strategy development, and product registration and application. During my stay in the United States, I engaged in medical research at the University of Massachusetts Medical School and Harvard Medical School for more than 10 years and gained extensive clinical/medical research experience with more than 30 internationally circulated medical publications. Since 2010, I worked for the US Food and Drug Administration (FDA) and served as a senior review expert for nearly 10 years, responsible for clinical research and drug safety review. After returning to China, I have worked for Shanghai Henlius Biotechnology Co., Ltd. and Nanjing Reindeer Medical and accumulated multi-faceted corporate operation/management experience in the development of immune and cell therapy products, as well as domestic and international clinical trial/regulatory affairs operations. 

Dr. Hu has more than two decades of experience in medical product development and regulations including 2 years at Becton Dickson, 6 years at GlaxoSmithKline, 2 years at Metabolon and 11 years at US FDA. 

Prior to joining Genetron Health as the Chief Medical Officer in April, 2020, Dr. Hu was the Deputy Director of the Division of Molecular Genetics and Pathology in the Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, FDA. His team was responsible for regulating molecular oncology diagnostic products (liquid biopsy, early cancer screening, course detection, micro-residual disease, etc.), companion diagnostics, gene testing, artificial intelligence in anatomical and cytological pathology devices. Hu received 10 agency-level awards and eight center-level achievement awards at FDA. 

Some of the notable FDA approvals by his team include the first laboratory-developed test (LDT)-based companion diagnostics (Myriad Genetics' BRACAnalysis CDx); the first next generation sequencing (NGS)-based LDT as companion diagnostics (CDx) (Foundation Medicine’s FoundationFocus CDxBRCA); the first NGS-based CDx kit (ThermoFisher Oncomine Dx Target Test); the first NGS-based LDT for tumor profiling (MSK-IMPACT and later on FoundationOne CDx); the first liquid biopsy test for NSCLC (Roche Cobas EGFR Mutation Test v2); and FDA’s only two approved cancer screening tests in the last decade (Exact Sciences’ Cologuard and Epigenomics’ Epi ProColon).  

Dr. Hu received his Ph.D. degree in veterinary physiology & pharmacology and M.S. in reproductive endocrinology at The Ohio State University. 

Dr. Victor Shi is Managing Partner of Serica Partners, a venture capital fund focusing on investing in IVD and medical devices in China.  Dr. Shi is also Founder and Chairman of careLYFE, a women’s health company located in Suzhou, China. 
Dr. Shi has 30 years’ experience in life science R&D, sales and marketing, business development, and investment. Previously he was CEO of Adicon Clinical Laboratories, a leading independent clinical laboratory in China, Co-Founder and CEO of NuProbe, a liquid biopsy technology company, and President Asia Pacific of QIAGEN, a NASDAQ- and Frankfurt-listed leading provider of sample to insight solutions for molecular testing. He has held senior positions at Aura Partners, Bridge Pharmaceuticals, Genospectra, and Pappas Ventures.  In addition, he was a faculty member of School of Medicine of National University of Singapore, where he set up the sample bank of Asian molecular epidemiology, and a cancer research scientist at Merck & Co. 
Dr. Shi is a Founding Director of Bayhelix Group, a global association of Chinese life science business executives, and was elected Chairman from 2018 to 2019.  He also serves on the Hong Kong Stock Exchange Biotech Advisory Committee.  Meanwhile, Dr. Shi is a council member of Shoulder Action, a charitable NGO that is dedicated to reading skill development in China rural areas.  

Jian-Bing Fan, Founder and CEO, AnchorDx - a company that is focusing on the development of NGS-based clinical diagnosis products for cancer screening and early detection - has over 20 years of experience in human genome research and microarray/next-gen sequencing technology development. He played important roles in developing the BeadArray technology and a series of genomics products at Illumina for high throughput genotyping, gene expression and methylation analysis. Prior to joining Illumina, Dr. Fan was the Manager of Polymorphism Research at Affymetrix. While at Affymetrix, he spearheaded the development of high-density oligonucleotide array technology and its application in large-scale SNP identification and genotyping. Previously, Dr. Fan was a senior research fellow at UCSF/Stanford Human Genome Center. He was a key scientist involved in all aspects of the Center’s scientific operation, such as large-scale physical mapping and sequencing of the human genome. Dr. Fan received his PhD in Genetics from Columbia University. He has authored more than 190 original articles and book chapters, published one book, been granted 42 US/world patents, and served/serving on the editorial board of scientific journals Genome Research and Translational Cancer Research, and was an executive editor of Genomics, and Editor-in-Chief, Genomics Data, published by Elsevier. 

Dr. Jie Wang is a professor at the Jiangsu Institute of Clinical and Translational Research and Jiangsu Province Hospital. He serves on the editorial boards of several peer-reviewed journals in the United States, United Kingdom, and Japan. Dr. Wang's reputation in medical field has been evidenced by his profound professional career: Director of Skirball Center/Cardiovascular Research Foundation, Executive Vice President of the Jiangsu Institute of Clinical and Translational Research, Dean of Medical School/Nanjing Medical University, Associate Professor at Columbia University and founders of several start-ups.  
Dr. Wang graduated from New York Medical College and completed his post-doctoral research and clinical training at Duke University and Harvard University. He has published more than 200 professional articles/abstracts/book chapters, and has authored over 40 patents. 

Bob Wang joined Agena Bioscience in September 2015 as General Manager, Greater China. Bob most recently was Marketing Director, Greater China for QIAGEN where he was responsible for leading the development of its life science and molecular diagnostic immunoassay commercial strategies. Prior to this, Bob was Director, Sales & Business Development for Hologic, formerly Gen-Probe, overseeing APAC M&A and China sales growth in molecular diagnostics. Bob also held senior positions in Business Development, Marketing, Sales, and Regulatory Affairs at Hologic, Life Technologies, Applied Biosystems, and the Chinese Human Genome Center, covering genomics, bioinformatics, and next generation sequencing. Bob holds an M.B.A. from the University of British Columbia and a Bachelor of Science degree in Biology from East China Normal University.  

Dr. Jian Han is a molecular biologist, and currently serves as faculty investigator at the HudsonAlpha Institute for Biotechnology in Alabama. Dr. Han has been involved in developing immune repertoire sequencing technology since 2007, and his work has opened new areas for research and clinical application. He has developed several generations of multiplex PCR technologies, from which Dr. Han founded several biotech companies, including Genaco, Diatherix, iCubate, iRepertoire. Dr. Han graduated from Suzhou Medical College, and received a PhD in Medical Genetics from the University of Alabama at Birmingham. 

Dr. Wang graduated from Fudan Medical college, started his academic career as a postdoctoral researcher in Boston University, an assistant professor in UT Memphis; pharmaceutical industry (GSK, Roche, Schering/Bayer, Aret), and CROs (CrownBio & Innoland), with ~100 publications in research articles, invited reviewers, book chapters, and patent applications.

Dr. Hu, graduated from West China Medical Center of Sichuan University, has been engaging in non-clinical drug evaluation and project management for more than 20 years in West-China Frontier PharmaTech. co. Ltd.  
Decade of experience in pharmacology and toxicology evaluations, acquaintance with both domestic and international guidance and regulations and certifications of PMP and PRINCE2, promote thousands of non-clinical pharmaceuticals evaluation, including small molecular chemical drugs, traditional Chinese medicine, biological products, etc. 

Dr. Villinger holds a DVM/PhD from the University of Zurich in Switzerland, and has focused most of his 35 years in research on immune responses to infectious diseases. He is the current Director of the New Iberia Research Center (NIRC) and a professor of Biology at the University of Louisiana at Lafayette. NIRC is one of the largest center for primate research in the US with over 8500 primates. During his career at Emory University (Atlanta, GA) and now at NIRC Dr. Villinger has developed and optimized nonhuman primate models of human disease, including Dengue, zika, Babesia, Lymhocryptovirus, Ebola, SARS-CoV2 and predominantly HIV using the Simian Immunodeficiency Virus (SIV) models. This includes studies of mucosal virus acquisition, the role of adaptive and innate defenses and inflammation in viral maintenance and cure. He directs several HIV vaccine studies including a NIH funded SIV Vaccine Evaluation Unit as well as studies on vaginal and rectal microbicides to prevent mucosal HIV acquisition.  With Dr. Santangelo (GATECH, Atlanta), Dr Villinger has pioneered novel strategies to map virus and immune mechanisms in real time using a combination of ImmunoPET/CT and histological imaging to address viral and immune cell dynamics in vivo, including monitoring sites of residual SIV during antiretroviral therapy and the sites of functional reservoirs from which virus rebounds post ART interruption.  These novel technologies are being used to address mechanistic questions of viral and immune dynamics during therapeutic interventions.  

Dr. Xiaomeng Wang is an Associate Professor at the Centre for Vision Research, Duke-NUS Medical School, Principal Investigator at Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), and Principal Investigator and Director of Laboratory and translational research at Singapore Eye Research Institute. Prior to this appointment, Dr. Wang worked as an Associate Professor at the Lee Kong Chian School of Medicine, Nanyang Technological University Singapore. Dr. Wang obtained her BSc. in Biology at Beijing Normal University, China, and her PhD in Genetics at Newcastle University, UK. Thereafter, she undertook post-doctoral training at Manchester University and University College London, UK. Dr. Wang’s lab focuses on understanding the molecular and cellular mechanisms underlying fibrovascular complications, especially those in the eye with the ultimate goals to 1) identify reliable biomarkers for disease prediction, diagnosis, and prognosis; 2) develop novel therapeutic approaches for more effective disease management; 3) establish disease-relevant in vitro, ex vivo and in vivo models; 4) develop minimum invasive and sustained drug delivery system. 

Dr. Henry Li leads CrownBio's Global Scientific Research and Innovation Division, focusing on developing new products and services supporting drug discovery and translational sciences. Before joining CrownBio, Dr. Li has many years of biopharmaceutical, as well as academic R&D, experience in cancer and viral infection, including leadership roles as R&D Director/Senior Director in several US-based biotech companies. Dr. Li earned his Ph.D. in Molecular Biology/Biochemistry from the University of California (Irvine) and completed his postdoctoral training at UCLA School of Medicine. He has published ~70 manuscripts and edited 3 books in the biopharmaceutical areas.

Dr Sun acquired his Ph.D. from Imperial College London, UK with research focus on molecular signaling and related drug researches in diabetes, obesity and neural endocrinology. He started his industrial career by joining GSK and Novo Nordisk, taking responsibilities in leading the pharmacology researches in drug candidates for treating metabolic diseases. Dr Sun later extended his experience in metabolic animal models by joining CrownBio. He is now leading the pre-clinical development team in Pegbio. He has successfully taken 5 peptide or protein drugs into IND in China and US, and established his research position in metabolic diseases by publishing over 20 peer-reviewed articles.

Kevin Chen is the founding partner of BioTrack Capital and has spent over 21 years as a scientist, entrepreneur and investor in the healthcare space.  
BioTrack Capital is a healthcare dedicated VC fund founded in 2017 with AUM close to US$ 1billion.  
BioTrack has been recognized as a leading Chinese healthcare VC by entrepreneurs, investors and named top 10 China healthcare VC by China Venture, Zero to IPO and CVinfo. Prior to founding BioTrack, Kevin was Partner at Sequoia China responsible for healthcare investment where he led Sequoia China’s investment in healthcare across different stages and subsectors. Before Sequoia, he was the Head of Everbright’s first healthcare fund, Everbright Healthcare Fund I, a China focused healthcare fund.  
At BioTrack, Sequoia and Everbright, Mr. Chen led investments in over 50 leading healthcare companies in China including biggest Chinese genomic company BGI (300676 SZ) , first public listed Chinese Biotech company Betta Pharma (300558 SZ) , leading biopharma company Zai Lab ( ZLAB, Nasdaq), MedTech leader Venus Medical ( 02500.HK) and China’s biggest digital healthcare company We-Doctor。  
Before Everbright, he was President, COO and CFO of ShangPharma, a start-up CRO (Contract Research Organization) company he joined as a co-founder in 2008. During Kevin’s tenure, he grew the business from a small family owned business into second biggest CRO in China. He successfully led the IPO of the company on the NYSE in 2010.  
Before that, Kevin had spent time at CITIC Capital and DuPont both in the US and China, and was a research scientist at a San Diego based biotech company: Ligand Pharmaceuticals.  
Kevin holds an MBA from Kellogg, a Master’s Degree in Medicinal Chemistry & Biochemistry from Tulane University and a Bachelor’s Degree in Chemistry from Nanjing University. 

Mr. GAO Song (高嵩), aged 49, has served as Adicon Group Senior vice president and COO since December 2019.
Prior to joining our Group, Mr. GAO served as a general manager of Shanghai Yaoshiquanyun Health Technology Development Co., Ltd. (上海鑰世圈雲健康科技發展有限公司) , He also held various positions at GlaxoSmithKline(葛蘭素史克),
as vice president and head of respiratory BU, head of commercial excellence department, head of hepatitis sales department.
Mr. GAO received his bachelor’s degree in biochemistry from Fudan University (復旦大學) in China in July 1995, and his master’s degree in business management from China Europe International Business School (中歐國際工商學院) in September 2009.

Jacky CHEN, Founding Partner of Yusnsheng BioVenture. Yuansheng BioVenture is managing three RMB and USD funds, with total AUM amounted 7 billion RMB. Yuansheng BioVenture focuses on life science area and invest in companies with great potential in biotech, new drug discovery, medical devices and healthcare services fields. Since its establishment in 2013, Yuansheng BioVenture has made investments in more than  100 companies in healthcare industry. He completed the merger and withdrawal of multiple projects, IPO exit and realized huge return for investors.  
Mr. Chen has more than 20 years experiences in multi-national corporations and healthcare investment. He has both extensive domestic network, expertise and global perspective. Before founding Yuansheng, he also worked at CXC Capital, GL Capital and Olympus Capital.  Mr. Chen also attained his MBA degree in Cornell university and bachelor degree in Sun Yat-sen university. 
Mr Chen’s past investment cases include Ascentage Pharma (6855.HK), Henlius Biotech(2696.HK), Kintor Pharma(9939.HK), Basecare Medical(2170.HK), BrightGene (688166), Allist Pharma(688578), Kawin Technology(688687), Nano-Micro(688690), YHLO Biotech(688575), ShengNuo Biotech(688117), Zylox-Tonbridge(2190.HK), Quantum-Si(NASDAQ), Creative Sciences, PegBio, Smartee,  Capitalbio Technology , Innovita, Lifereal,  Ark Biosciences, Jingfeng Pharma (000908), BGI Genomics (300676), Kangning Hospital (2120.HK)， etc. 

Dr. Ye Edward Tian holds an BS in Chemistry from Tsinghua University, Master of Biophysics in China Academy of Sciences, and Doctor of Pharmacology and Neurobiology from Michigan State University. He served several pharmaceutical companies including Parke-Davis, Pfizer and Transtech Pharma. With his rich work experience in international Fortune 500 pharmaceutical companies and biotechnology companies over the past three decades, he was the leader for several drug development projects. He joined Impact Therapeutics in 2009 for its founding and operations after returning to China and was the CEO of Impact Therapeutics for 5 years. The company has emerged as one of the fastest growing local bio-pharmaceutical companies in China. 

Over the past two decades, Dr. Lin Ni has been working in life sciences field as a drug discovery scientist, manager of multinational company and venture capitalist. 

Before joining TF Capital, Dr. Ni was the managing director of 6 Dimensions Capital and SDIC Fund Management. She was also the director of corporate strategic investment in Wuxi AppTec. During that period, she participated and led several investment projects in life science and pharmaceuticals in China and USA.

Previous to that, as the senior manager of business development department in Pfizer, she was in charge of Pfizer’s research collaboration and development in Japan and supported Pfizer’s licensing, collaboration, strategic investment and M&A in Asia-Pacific region.

At the early stage of her career, she started as a scientist for drug discovery in Bayer Kyoto Research Center and got her Ph.D in Pharmacology in Osaka University.

Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments.

Professor Albert Cheung Hoi Yu received his PhD from the University of Saskatchewan, Canada and spent subsequent years in UCSF, Stanford, HKUST and Peking University.

Professor Yu is a world-renowned bio-entrepreneur and scientist with over 30 years of experience in the field of neuroscience and molecular diagnostics. He has published over 170 peer review scientific papers, several commentaries in Science and Nature Biotechnology, and 9 books. He found HKLife and has invented numerous technologies including 73 global patents. Professor Yu creates the BioRadar® system which aims to accelerate the development of precision medicine and guided treatment. His broad cross-cultural experience and an active involvement in both the academic and business create an extensive global network and contacts in China. He is now an important facilitator of dialogue regarding the development of biotechnology in Asia, putting Hong Kong onto the global biotechnology map. Recently, he pushes forward a major international biotech convention - BIOHK, so as for all of us to have a global biotech platform in Asia to showcase our accomplishments, exchange ideas, trade our products, fundraising, and more.

Jay Dong is CEO, Co- Founder , HPlanetBio, Partner at Kunpeng Healthcare Investment. Also Founding Co-President of Academia-Industry Consortium on Innovation and Entrepreneurship of China CSCB,  and a co-founder and Secretary General and Vice Chairman of Precision Medicine & Companion Diagnostics Committee of CSBT. Guest Professor of Wuhan University Medical Research Institute.  
He earned an M.B.A (MIT), M.A. (Tufts) and Master of Medicine from Peking Union Medical College.  
First ten years of his career: Jay started his career as a researcher and R&D scientist at Tufts University School of Medicine, LeokoSite and Millennium Pharmaceuticals (Now Takada). Next twenty years: Jay focused on marketing, commercialization and management, then he marched into business management as a marketing and business leader with Becton Dickinson (BD) Bioscience in the United States and in Singapore, and since 2008, he was the founding General Manager of China/Asia Pacific, later Global VP, of CST, building the company from “scratch” in China. Jay has been invited speaker at Peking University, Fudan, Wuhan, as well as MIT MBA EMBA classrooms etc.  
Additional voluntary social responsibilities included board member on a list of non-profit and industry organizations such as BayHelix Group, Sino American Biomedical and Pharmaceuticals Association(SABPA), Shanghai American School. 

Kaibing Zhou, Vice President of China Investment Development Promotion Association and President of Hangzhou Venture Capital Association, he graduated from Applied Mathematics in 1988. He is a Certified Public Valuer and researcher. He was a visiting scholar in the Department of Economics at Boston College. He is one of China's first intangible asset, a technology finance researcher and practitioner, and a pioneer in cross border venture capital. 

Mr. Zhou Liyun, the founder of PharmCube.He has rich experience in areas such as governmental science and technologyproject management, pharmaceutical enterprise business development, investmentand M&A, as well as R&D management over the past 15 years. Since itsestablishment in 2013, PharmCube has been committed to promoting digitalrevolution in pharmaceutical industry by fostering innovation and growthempowered by data.

Josie Zhou has extensive experience serving global and local biopharmaceutical clients across a broad range of topics in China, with a focus on R&D ,launch, growth strategy, commercial model innovation and organization 
Josie has authored articles on China healthcare innovation and most recently the COVID-19 impact on the China biopharma, and she has been one of co-authors on the yearly McKinsey China healthcare insights in partnership with Biocentury on “Bridge to innovation” series since 2017. 

Yuwen Liu, Founding Partner of BOHE Angel Fund, and has invested in more than 30 early-stage biomedical start-ups such as Etern Therapeutics, Magic Medical, Neurophth Biological, Kanova Biopharma, ImmVira Group, Shuimu Biosciences, Neural Galaxy, Sironax, etc. She founded the two major technology incubation brands, Beijing Bio2 and Adock Innovation, and cooperated with BOHE Angel Fund to achieve precise incubation and technology transfer of early life and health technologies.  
Before the launch of BOHE Angel Fund, she is the CEO of BioBAY and build BioBAY from scratch to one of the most dynamic biotech cluster in China with ~400 start-up companies located in. She served and incubated a series of biotech companies including Innovent, BrightGene, NanoMicro, Kintor, HOB Biotech and Alphamab Oncology and launched companies including Yuanbio Venture Capital and Qiagen (Suzhou) Translational Medicine. Previously, she served as the China Chief Representative of Perrigo and worked as QA Engineer, QC manager, QA/QC manager and BD manager. Graduated from China Pharmaceutical University with master degree in Pharmaceutics, she is a licensed pharmacist. 

 

Dr. Kenneth Carter is a dynamic biotechnology industry executive and scientific leader with deep experience in early-stage company development. He has been involved in starting and guiding several biotechnology companies as a co-founder, advisor, CEO, and/or member of the Board of Directors including NexImmune (NASDAQ: NEXI) which he co-founded and served for many years as Chairman and CEO, and Seneca Biopharma (NASDAQ: SNCA) where he served as Executive Chairman. From 1999 until 2009, Dr. Carter was a co-founder and the CEO of Avalon Pharmaceuticals (NASDAQ: AVRX, now part of AbbVie). Under his leadership, Avalon developed a pipeline of cancer drug candidates based on a novel high-throughput genomic screening technology, and completed an IPO and multiple partnerships with top 10 pharmaceutical companies. Earlier in his career, Dr. Carter was head of gene mapping at Human Genome Sciences, Inc. where he was involved in the discovery of dozens of novel human proteins with therapeutic or diagnostic potential, particularly for the treatment of cancer. Dr. Carter is also engaged in a range of educational and teaching activities and holds an adjunct faculty position at Johns Hopkins University, where he teaches a course titled “Creating a Biotechnology Enterprise”. 

 

Over the last 13 years, Fangning has served leading Pharma, biotech and Medtech companies on business strategy, R&D, BD, organization transformation etc. 
Selected engagements include: 

• Supported a leading China Biotech on IPO preparation 
• Supported a leading China biotech on corporate strategy & strategic partnership    
• Supported an MNC pharmaco in formulating China long-term growth strategy  
• Developed China innovation strategy for a leading global healthcare company  

Dr. Haibin Wang, Bachelor of Science in Microbiology, Shanghai Fudan University, Ph.D. in Pharmaceutical Analysis, Zhejiang University.

She is a professor-level senior engineer, licensed pharmacist, currently president of Zhejiang Borui Biopharmaceutical Co., Ltd., Special Allowance Expert of the State Council, Vice Chairman of China Protein Quality Alliance, Member of Professional Committee of Biopharmaceuticals and Quality Research Experts of Chinese Pharmaceutical Association, Zhejiang Deputy Chairman of the Biopharmaceutical Committee of the Provincial Pharmaceutical Association. She has been engaged in biopharmaceuticals for more than 20 years and has extensive experience in registration, research and commercial production of microbial fermentation products and biotech drugs. She has won multiple scientific and technological awards at the provincial and ministerial level, published nearly 40 articles in core journals in China and abroad, and nearly 20 invention patents.

Joan Shen obtained Ph.D. in life science and is a licensed physician with board certification in US. She had postdoctoral trainings in endocrinology, psychopharmacology

and clinical pharmacology. Being responsible for global clinical development programs cross phase 1-4, she worked in Eli Lilly & Co, Wyeth and Pfizer in US, and gained extensive experiences of working with FDA, EMEA, CFDA, PMDA, KFDA and etc.

Joan was sent by Pfizer in 2011 as the China Clinical Head. She later joined Hengrui Pharmaceutical as the CMO. In Hengrui, she built the largest clinical team among China domestic pharmas and led the successful conduction of clinical trials in China, USA and Australia. Joan joined Janssen Pharmaceutical Companies

of Johnson & Johnson as the China Development Head in 2015, where she led multiple successful NDA approvals by CFDA. During this time, she was elected as the co-chair of RDPAC R&D core team. Joan joined I-Mab Biopharma as the Head of R&D in 2017 and was promoted to CEO in October 2019.

Joan is elected as the executive committee member of China New Drug Research Evaluation Committee. She holds academic positions as the guest professor of Beijing University Clinical Research Institute she was the adjunctive professor of Indiana University School of Medicine.